The approach to early Parkinson's disease denotes the communication of the diagnosis and important decisions, such as when and how to start treatment. Evidence based medicine and guidelines indicate which drugs have robust evidence of efficacy and tolerability in this specific population. However, de-novo patients may show different characteristics and they may be in a different phase of their disease. In this review, we will give an insight into the appropriate time therapy should be started and the actual knowledge about disease modification therapies. Moreover, the drugs indicated for early treatment will be considered and an indication for the use of these drugs will be given with the support of the actual knowledge.
CITATION STYLE
Stocchi, F., Vacca, L., & Radicati, F. G. (2015, February 25). How to optimize the treatment of early stage Parkinson’s disease. Translational Neurodegeneration. BioMed Central Ltd. https://doi.org/10.1186/2047-9158-4-4
Mendeley helps you to discover research relevant for your work.